Twist Bioscience Corporation (TWST) financials

NASDAQ · Healthcare · Biotechnology · 979 employees · CEO Emily Marine Leproust

Price: $152.78 -11.92%
Market cap: $10.1B
Enterprise value: $10B
Last report: Q3 '26 filed 2026-08-03
Next report: 2026-11-12 EPS est. -$0.38

Revenue (TTM)$432M+19.2% vs a year agoLast 4 quarters; bars = each quarter

Operating margin (TTM)-31.9%+7.4 pp vs a year agoOperating income -$138M

Net income (TTM)-$137M-60.5% vs a year agoAfter tax, incl. non-operating gains

Free cash flow (TTM)-$93.1M-35.5% vs a year agoCapex $40.1M

Diluted EPS (TTM)-$2.22-52.1% vs a year agoSum of the last 4 quarters

Net cash$73.2M-57.6% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap: $10.1B
Revenue: $432M
Revenue growth: +21%
Profit margin: -31.7%
P/E: -68.8×
P/S: 23.3×
EV / EBITDA: -93.1×
Free cash flow: -$93.1M
Net income: -$137M
Revenue estimate: $456M
Earnings: 2026-11-12
Dividend: –

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

Last report (2026-08-03): revenue beat by 3.4%, EPS missed by 10.6%Revenue $118M vs $115M expected (+3.4%); EPS -$0.56 vs -$0.51 (-10.6%).
Revenue growth accelerating: 23.2% year on yearQ3 '26 revenue $118M, against an average of 17.7% over the four quarters before.
Operating margin -31.9% (TTM), +7.4 pp on a year agoOperating income grew 3.2% while revenue grew 19.2%.
Capex 9.3% of revenue (a year ago 4.9%)$40.1M invested in the last 4 quarters (+127.8% on a year earlier). Free cash flow -$93.1M.
Diluted share count up 2.0% in a year62.4M diluted shares in Q3 '26, 61.2M a year earlier.
Net cash $73.2MCash + short-term investments $167M, debt incl. leases $93.6M; a year ago net cash $173M.

Last quarter: Q3 '26

Quarter ended 2026-06-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

	Q3 '26	Year ago	Change
Revenue	$118M	$96.1M	+23.2%
Gross margin	52.8%	53.4%	-0.6 pp
Operating income	-$36.3M	-$30.1M	-20.5%
Operating margin	-30.6%	-31.4%	+0.7 pp
Net income	-$35.1M	$20.4M	-271.9%
Diluted EPS	-$0.56	$0.33	-269.7%
Operating cash flow	$1.12M	-$1.4M	+179.6%
Capex	$9.66M	$9.17M	+5.4%
Free cash flow	-$8.55M	-$10.6M	+19.1%
R&D	$18M	$18M	-0.1%
Stock-based compensation	$18.2M	$16.1M	+13.2%

Reported vs consensus

2026-08-03

	Actual	Consensus	vs consensus
Revenue	$118M	$115M	+3.4%
EPS (as estimated)	-$0.56	-$0.51	-10.6%

From the report of 2026-08-03 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.

EPS vs consensus

last 8 reports

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Revenue by business line

stacked, quarterly

Segment	Q3 '26	y/y	Share	TTM	TTM y/y
Ngs Tools	$61.8M	+11.8%	52.2%	$225M	+12.1%
Antibody Discovery	$56.6M	+907.7%	47.8%	$167M	+650.2%
Synthetic Genes	–	–	–	–	–
Oligo Pools	–	–	–	–	–
Dna And Biopharma Libraries	–	–	–	–	–

Revenue by region

share of total

Segment	Q3 '26	y/y	Share	TTM	TTM y/y
Americas	$77.3M	+30.1%	65.3%	$257M	+16.4%
EMEA	$33.6M	+9.4%	28.4%	$144M	+24.9%
Asia Pacific	$7.5M	+26.4%	6.3%	$30.7M	+17.4%

Segment profits

Operating income per reported segment, read from the segment note of each 10-Q / 10-K (the profit split most data feeds leave out).

Segments in Q3 '26

Segment	Revenue	y/y	Operating income	y/y	Margin	Margin a year ago	TTM operating income
Reportable Segment	–	–	-$36.3M	-20.5%	–	–	-$145M

Operating income by segment

quarterly

Segment operating margin

quarterly

Fourth quarters are derived: the 10-K reports the full year, minus the three quarters of the 10-Qs.

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 4 quarters

cash flow statement

Operating cash flow: -$53.1M
Capex: -$40.1M
Buybacks: -$18K
Dividends: $0
Acquisitions: $0
Net debt issued: $0
Stock-based compensation: $66.5M
Free cash flow: -$93.1M
Returned to shareholders / FCF: -0.0%

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years

	Now	5y average	Where today sits in the 5-year range
P/E (TTM)	-68.8×	–	–
EV / EBITDA	-93.1×	–	–
EV / Sales	23.2×	12.0×	3.9× – 36.0×
Price / FCF	-108.0×	–	–
Price / Book	21.4×	4.4×	1.8× – 8.9×
FCF yield	-0.9%	-7.3%	-14.8% – -2.6%
Return on invested capital	-24.6%	-28.5%	-39.6% – -23.2%
Return on equity	-29.9%	-29.4%	-44.2% – -16.4%

Analysts

Consensus target $153.70 (+0.6%)
range $89.00 – $215.00 · rating Buy

Strong buy0

Buy11

Hold2

Sell2

Strong sell0

Outlook

Analyst consensus for the coming fiscal years and what it implies at today's price.

Consensus estimates

Fiscal year	Revenue	Growth	EPS	Growth	P/E at today's price	Analysts (EPS)
FY2026	$456M	+21.2%	-$2.14	-64.8%	-71.3×	4
FY2027	$549M	+20.2%	-$1.31	+38.8%	-116.5×	5
FY2028	$646M	+17.7%	-$0.87	+33.4%	-175.0×	8
FY2029	$773M	+19.8%	-$0.06	+93.0%	-2,485.2×	3
FY2030	$1.01B	+30.7%	$0.94	+1,620.9%	163.4×	1

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Income statementRevenue, costs, operating income, net income and EPSOpen Balance sheetCash, investments, assets, debt, liabilities and equityOpen Cash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Every reported line

All 238 figures Twist Bioscience Corporation tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).

Line (SEC label)	Latest quarter	Year ago	y/y	Latest FY	Prior FY	y/y
Accounts Payable, Current	$17M	$12M	+42.2%	$11.1M	$1.63M	+580.6%
Accounts Receivable, after Allowance for Credit Loss, Current	$65.1M	$49.9M	+30.5%	$57M	$34.9M	+63.4%
Accounts Receivable, Allowance for Credit Loss	$600K	$500K	+20.0%	$600K	$700K	-14.3%
Accrued Liabilities, Current	$20.5M	$19.5M	+4.7%	$23.1M	$15.1M	+52.6%
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$112M	$89.3M	+25.1%	$95M	$75.6M	+25.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax	-$655K	-$864K	+24.2%	-$627K	-$522K	-20.1%
Additional Paid in Capital	$1.88B	$1.77B	+5.9%	$1.79B	$1.72B	+4.6%
Advertising Expense	–	–	–	$7M	$5.2M	+34.6%
Amortization of Intangible Assets	$300K	$300K	0.0%	$1.1M	$4.1M	-73.2%
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6.06M	3.72M	+62.8%	5.19M	5.09M	+2.0%
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	$18.2M	$16.1M	+13.1%	$64.5M	$51M	+26.5%
Asset Impairment Charges	$02025-09-30	$0	–	$0	$44.9M	-100.0%
Assets	$672M	$644M	+4.5%	$642M	$614M	+4.5%
Assets, Current	$321M	$340M	-5.4%	$333M	$347M	-4.0%
Assets, Fair Value Disclosure	$125M	$217M	-42.7%	$200M	$250M	-20.1%
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	–	–	–	$0	$0	–
Capital Expenditures Incurred but Not yet Paid	-$2.2M	$493K	-545.6%	$2.41M	$92K	+2,517.4%
Capitalized Computer Software, Amortization	–	–	–	$2.9M	$2.6M	+11.5%
Capitalized Computer Software, Net	$3.2M2025-09-30	$5.2M	-38.5%	$3.2M	$5.2M	-38.5%
Cash and Cash Equivalents, at Carrying Value	$117M	$201M	-41.7%	$183M	$226M	-19.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$120M	$204M	-41.4%	$185M	$229M	-19.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	-$5.29M	-$9.04M	+41.5%	-$43.7M	-$60.1M	+27.3%
Commodity Contract Asset, Current	$6.19M	–	–	–	–	–
Common Stock, Capital Shares Reserved for Future Issuance	861K	795K	+8.3%	716K	611K	+17.2%
Common Stock, Par or Stated Value Per Share	$0.00	$0.00	0.0%	$0.00	$0.00	0.0%
Common Stock, Shares Authorized	200M	200M	0.0%	200M	100M	+100.0%
Common Stock, Shares, Issued	62.7M	60.2M	+4.2%	60.6M	58.9M	+3.0%
Common Stock, Shares, Outstanding	62.7M	60.2M	+4.2%	60.6M	58.9M	+3.0%
Common Stock, Value, Issued	$1K	$0	–	$0	$0	–
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$35.1M	$20.2M	-273.7%	-$77.8M	-$208M	+62.7%
Contract with Customer, Asset, after Allowance for Credit Loss	$6.19M	$1.04M	+497.1%	$3.86M	$2.03M	+89.9%
Contract with Customer, Liability	$7.1M2026-03-31	$1.99M	+256.9%	$6.88M	$2.13M	+223.0%
Contract with Customer, Liability, Current	$6.47M	–	–	–	–	–
Contract with Customer, Liability, Noncurrent	$5.67M	–	–	–	–	–
Contract with Customer, Liability, Revenue Recognized	$2.9M	$1.7M	+70.6%	$1.4M	$1.7M	-17.6%
Cost of Revenue	$55.9M	$44.8M	+24.9%	$186M	$180M	+3.3%
Costs and Expenses	$155M	$126M	+22.6%	$513M	$534M	-3.9%
Current Federal Tax Expense (Benefit)	–	–	–	$0	$0	–
Current Foreign Tax Expense (Benefit)	–	–	–	$692K	$540K	+28.1%
Current Income Tax Expense (Benefit)	–	–	–	$719K	$560K	+28.4%
Current State and Local Tax Expense (Benefit)	–	–	–	$27K	$20K	+35.0%
Debt Conversion, Converted Instrument, Amount	–	–	–	$0	$0	–
Debt Securities, Available-for-sale	$49.4M	$49.4M	0.0%	$49.4M	$50.1M	-1.4%
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	$2K	$0	–	$69K	$119K	-42.0%
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	$41K	$2K	+1,950.0%	$0	$0	–
Debt Securities, Available-for-sale, Amortized Cost	$49.4M	$49.4M	0.0%	$49.3M	$50M	-1.3%
Deferred Federal Income Tax Expense (Benefit)	–	–	–	$0	$0	–
Deferred Foreign Income Tax Expense (Benefit)	–	–	–	$0	$0	–
Deferred Income Tax Expense (Benefit)	–	–	–	$0	$0	–
Deferred Revenue, Current	$6.47M	$6.32M	+2.2%	$6.88M	$2.13M	+223.0%
Deferred State and Local Income Tax Expense (Benefit)	–	–	–	$0	$0	–
Deferred Tax Assets, Gross	$399M2025-09-30	$379M	+5.3%	$399M	$379M	+5.3%
Deferred Tax Assets, Net	$02025-09-30	$0	–	$0	$0	–
Deferred Tax Assets, Net of Valuation Allowance	$15.4M2025-09-30	$18.2M	-15.5%	$15.4M	$18.2M	-15.5%
Deferred Tax Assets, Operating Loss Carryforwards	$232M2025-09-30	$227M	+2.4%	$232M	$227M	+2.4%
Deferred Tax Assets, Other	$12.3M2025-09-30	$14.3M	-13.8%	$12.3M	$14.3M	-13.8%
Deferred Tax Assets, Tax Credit Carryforwards, Research	$67.6M2025-09-30	$59.6M	+13.5%	$67.6M	$59.6M	+13.5%
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	$13.4M2025-09-30	$13.4M	-0.2%	$13.4M	$13.4M	-0.2%
Deferred Tax Assets, Valuation Allowance	$383M2025-09-30	$361M	+6.3%	$383M	$361M	+6.3%
Deferred Tax Liabilities, Gross	$15.4M2025-09-30	$18.2M	-15.5%	$15.4M	$18.2M	-15.5%

Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-Q 2025-12-31, 10-K 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-Q 2024-12-31, 10-K 2024-09-30, 10-Q 2024-06-30

Data as of 2026-11-02